Vaccines

Vaccinex is a clinical-stage biotechnology company focused on the development of targeted biotherapeutics for the treatment of serious diseases with unmet medical needs, including cancer and neurodegenerative disorders. The company's lead program, pepinemab (VX15/2503), is a humanized monoclonal antibody designed to block the activity of Semaphorin-4D (SEMA4D), a key mediator of neuroinflammation and an inhibitor of immune cell infiltration into tumors. Vaccinex is currently evaluating pepinemab in clinical trials for Huntington's disease and Alzheimer's disease, as well as in combination therapies for various oncology indications. Additionally, the company utilizes its proprietary ActivMAb and Natural Selection platforms to discover and develop high-affinity antibodies against complex membrane targets.